AK105

BIOLOGICAL12 trials

Sponsors

Akeso, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Liaoning Cancer Hospital & Institute

Conditions

Advanced Head, Neck and Chest CancerBreast Neoplasm FemaleGastrointestinal Tumors, Urinary System Tumors, Neuroendocrine TumorsHCCHepatocellular CarcinomaHodgkin's LymphomaLung CancerLung Cancer Non-small Cell Stage IV

Phase 1

A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma

CompletedNCT03722147

AkesoHodgkin's Lymphoma

Start: 2018-08-13End: 2021-12-31Updated: 2024-04-03

A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors

CompletedNCT04172506

AkesoHCC, Lung Cancer, Solid Tumor

Start: 2019-09-10End: 2022-01-30Updated: 2025-03-12

Phase 2

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

CompletedNCT03866967

AkesoNasopharyngeal Carcinoma

Start: 2019-03-27End: 2024-03-22Updated: 2025-02-27

A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

CompletedNCT04172571

AkesoHepatocellular Carcinoma

Start: 2018-11-22End: 2022-07-08Updated: 2024-05-30

A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Head, Neck and Chest Cancer

Start: 2020-05-09End: 2021-05-30Target: 140Updated: 2020-06-23

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Start: 2020-06-03End: 2021-05-30Target: 150Updated: 2020-06-17

A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.MSI-H or dMMR Advanced Solid Tumors

Start: 2020-03-31End: 2022-12-31Target: 138Updated: 2020-03-02

A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma

CompletedNCT04736810

AkesoNasopharyngeal Carcinoma

Start: 2021-02-25End: 2023-12-18Updated: 2025-03-07

Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolMGMT-Unmethylated Glioblastoma

Start: 2021-09-30End: 2023-11-01Target: 28Updated: 2021-09-05

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Liaoning Cancer Hospital & InstituteBreast Neoplasm Female

Start: 2022-07-31End: 2024-03-31Target: 42Updated: 2022-07-12

Phase 3

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

TerminatedNCT03866980

AkesoLung Cancer Non-small Cell Stage IV

Start: 2018-11-27End: 2023-12-31Updated: 2024-04-03

A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer

CompletedNCT03866993

AkesoLung Cancer Non-small Cell Stage IV, Squamous Cell Lung Cancer

Start: 2018-12-20End: 2022-01-14Updated: 2024-04-03

Related Papers

Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China

BMJ Open2025-03-012 citations

Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial.

2024-09-274 citations

Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.

Journal of Clinical Oncology2024-06-011 citations

Abstract PO2-06-09: A prospective phase 2 study on efficacy and safety of AK105, anlotinib combined with nab-paclitaxel (nab-P) as a first-line therapy in patients(pts) with advanced triple-negative breast cancer(TNBC)

Cancer Research2024-05-021 citations

Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial.

2024-02-074 citations

First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.

2024-01-3140 citations

A phase II study cohort of penpulimab plus anlotinib in patients with recurrent or metastatic non-squamous cell carcinomas of head and neck.

Journal of Clinical Oncology2023-06-01

Abstract OT2-08-01: A prospective phase 2 study on efficacy and safety of AK105, anlotinib combined with nab-paclitaxel (nab-P) as a first-line therapy in patients(pts) with advanced triple-negative breast cancer(TNBC)

Cancer Research2023-03-01

Perioperative penpulimab plus anlotinib combined with chemotherapy for locally advanced gastric cancer: A single arm, multicenter, phase II clinical trial.

Journal of Clinical Oncology2023-01-24

80P Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated overall survival results from a phase Ib/II study

Immuno-Oncology Technology2022-12-011 citations

571 Penpulimab for relapsed/refractory (R/R) classical hodgkin's lymphoma (cHL): Extended follow-up of the multicenter, single-arm, phase 2 study

Regular and Young Investigator Award Abstracts2022-11-011 citations

Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events

Frontiers in Immunology2022-06-2736 citations

Penpulimab plus anlotinib in patients with recurrent or metastatic head and neck squamous cell carcinoma after the failure of first-line platinum-based chemotherapy: A single-arm, multicenter, phase 2 study.

Journal of Clinical Oncology2022-06-011 citations

Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study.

Journal of Clinical Oncology2022-06-01

Survival outcome of patients with relapsed or refractory classical Hodgkin lymphoma who achieved remission during immune checkpoint inhibitors treatment.

Journal of Clinical Oncology2022-06-01

Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers.

2022-02-1514 citations

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)

Frontiers in Oncology2021-07-1363 citations

A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL).

Journal of Clinical Oncology2021-05-2011 citations

Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.

Journal of Clinical Oncology2021-05-2011 citations

Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.

Journal of Clinical Oncology2021-05-209 citations

5 more papers not shown